• NuVision Biotherapies raised £4.8 million in a Mercia Ventures-led round involving Pioneer Group to expand internationally and scale operations.
• Freenome debuted on Nasdaq in July 2026; its SimpleScreen CRC blood-based colorectal cancer screening program secured FDA approval in late July.
• The FDA granted Freenome’s SimpleScreen lung cancer screening test Breakthrough Device Designation in August 2026.
• 4D Medicine is finalizing its Series A; Inaphaea BioLabs’ drug evaluation prompted ValiRx to negotiate an exclusive license and fund preclinical development.
• SurePulse Medical’s wireless monitor demonstrated feasibility in preterm infants; Locate Bio’s peer-reviewed study supported LDGraft’s evidence base for bone regeneration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pioneer Group published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.